Citations

Clear

1792 citation(s) found for "Stephanie".

Longitudinal Heart Failure Medication Use and Adherence Following Left Ventricular Assist Device Implantation in Privately Insured Patients
Tan, Nicholas Y. , Sangaralingham, Lindsey R. , Schilz, Stephanie R., Dunlay, Shannon M.

Mayo Clinic

Journal of the American Heart Association | October 4, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.005776 | PMID 28974501 Get It

Background There are few data describing the longitudinal use of and adherence to heart failure medications following left ventricular assist device (LVAD) implantation. Methods and Results Using a large US commercial insurance database, patients who received an LVAD ( International Classification of Diseases, 9th Revision, Clinical Modification code 37.66) and survived to hospital discharge without heart transplantation between January 1, 2006, and March 31, 2015, were identified. Heart failure medication use from 3 months before 1‐year post‐ LVAD was examined using linked pharmacy claims. Differences in the proportion of patients taking heart failure medications post LVAD compared with pre LVAD were examined using McNemar test. Predictors of post‐ LVAD medication use and poor medication adherence (proportion of days covered <0.8) were identified via logistic regression. Among 362 patients (mean age, 57.4 years; 75.1% men), compared with pre LVAD , the proportion of patients taking anticoagulants and antiarrhythmics following LVAD increased; mineralocorticoid receptor antagonists, thiazide diuretics, and digoxin decreased; and β‐blockers, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and loop diuretics did not change. Pre‐ LVAD medication use was associated with post‐ LVAD use across all medication classes. The proportion of patients with poor medication adherence was 28.8%, 39.0%, and 36.0% for β‐blockers, angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, and anticoagulants, respectively. Many patients with poor adherence completely discontinued use of the medication. Conclusions Neurohormonal antagonist use after LVAD was inconsistent, perhaps reflecting uncertainty of therapeutic benefit in this population. Medication adherence post‐ LVAD was poor in many patients. Further work is needed to delineate the reasons for nonadherence after LVAD .
Improving Instructions to Stop the Bleed
Forsyth, Katherine L., Lowndes, Bethany R. , Jonson, Carl‐Oscar , Sztajnkrycer, Matthew D. , Heller, Stephanie F. , Blocker, Renaldo C., Forsyth, Katherine L., Prytz, Erik , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | September 28, 2017 | Volume: 61 | Issue: 1 | Pages: 588-592

10.1177/1541931213601631 Get It

The Stop The Bleed initiative was developed by the Department of Homeland Security to educate lay providers in bleeding reduction strategies. The current study evaluated: (1)three tourniquet instructions using a simulated tourniquet task and (2)participant confidence levels in tourniquet use and lay provider training. Thirty participants with limited clinical experience applied a tourniquet to a simulated limb using one of three instruction sets. Twelve of these participants (40%) participated in a tourniquet training session and focus group to discuss each instruction set. Participants preferred the most simple and pictoral instruction set, and identified opportunities for improvement in each set. Participant confidence in tourniquet use increased significantly following the task and the focus group. After the focus group, participant confidence in instructing lay providers on proper tourniquet use significantly increased. Adding key steps, contextual pictures, and indicators of success to instructions could support lay providers stop the bleed in life-threatening situations.
Feeding Tubes and Health Care Service Utilization in Amyotrophic Lateral Sclerosis: Benefits and Limits to a Retrospective, Multicenter Study Using Big Data
Sangaralingham, Lindsey R. , Shah, Nilay D. , Tilburt, Jon C. , Swetz, Keith M. , Peterson, Stephanie M, Hurt, Ryan T. , Dunlay, Shannon M. , Peterson, Stephanie M. Peck

Mayo Clinic

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | September 23, 2017 | Volume: 54 | Issue: No issue available | Pages: No page available

10.1177/0046958017732424 | PMID 28942701 Get It

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurologic disorder with predictable challenges regarding disease progression and end-of-life care. These include need for respiratory and nutritional support. Little is known about how such choices impact end-of-life health service utilization for these patients. Using OptumLabs Data Warehouse, a large administrative claims database with more than 150 million privately insured, geographically diverse enrollees, we sought to explore outcomes associated with the use of enteral nutrition (EN). Patients were of age ≥18 years, with first ALS diagnosis during calendar years 2006-2012, and 6 months of continuous health plan coverage before first diagnosis. EN use was identified using procedure codes. Data were summarized descriptively. Among 1974 patients with ALS, mean age was 60.0 ± 12.5 years, 41.8% were women, and 9.7% demonstrated use of EN. Median time from ALS diagnosis to evidence of EN was 211 days (interquartile range [IQR]: 70-426). Those receiving EN had greater aggregate comorbidity (47% with Charlson-Deyo Comorbidity Index ≥ 3 vs only 27% in non-EN subset). In total, 38.1% of patients had at least 1 hospitalization, with median time to hospitalization of 162 days. Unfortunately, the EN group ended coverage a median of 155 days after EN started (IQR: 63.5-388), thereby limiting ability to capture outcomes. Although many ALS patients were identified, EN use was lower than expected, due to being earlier in disease trajectory and lost to follow-up with transition from private insurance. As such, databases exclusively including privately insured patients may be suboptimal for detecting late complications of protracted illnesses.
Magnitudes of muscle activation of spine stabilizers in healthy adults during prone on elbow planking exercises with and without a fitness ball
Youdas, James W., Coleman, Kendra C., Holstad, Erin E., Long, Stephanie D., Veldkamp, Nicole L., Hollman, John H. , Hollman, John

Mayo Clinic

Physiotherapy Theory and Practice | September 18, 2017 | Volume: 34 | Issue: 3 | Pages: 212-222

10.1080/09593985.2017.1377792 | PMID 28922049 Get It

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA -Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia, X. , Northfelt, Donald W. , Margenthaler, Julie A. , Aft, Rebecca , Gray, Richard J. , Wilke, Lee G. , Haddad, Tufia C. , Moynihan, Timothy J. , Loprinzi, Charles L. , Barnell, Erica K. , Skidmore, Zachary L. , Feng, Yan-Yang, Krysiak, Kilannin , Guo, Zhanfang , Nehring, Leslie, Wisinski, Kari B. , Sanati, Souzan , Al‐Kateb, Hussam , Griffith, Obi L. , Griffith, Malachi , Doyle, L. Austin, Erlichman, Charles , Suman, Vera, Northfelt, Donald, Haddad, Tufia, Moynihan, Timothy, Loprinzi, Charles, Hieken, Tina, Krysiak, Kilannin , Griffith, Malachi , Griffith, Obi L , Suman, Vera J. , Goetz, Matthew P. , Burkard, Mark E. , Ademuyiwa, Foluso O. , Naughton, Michael J. , Tevaarwerk, Amyé , Hieken, Tina J. , Hoog, Jeremy , Mardis, Elaine R. , Hagemann, Ian S. , Vij, Kiran R , Ellis, Matthew J.

Mayo Clinic

Clinical Cancer Research | September 5, 2017 | Volume: 23 | Issue: 22 | Pages: 6823-6832

10.1158/1078-0432.ccr-17-1260 | PMID 28874413 Get It

Abstract Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor–positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA-mutant ER+ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces pathologic complete response (pCR) in PIK3CA mutant ER+ breast cancer. Experimental Design: Potential eligible patients with clinical stage II/III ER+/HER2− breast cancer were preregistered and received anastrozole (goserelin if premenopausal) for 28 days in cycle 0 pending tumor PIK3CA sequencing. Patients positive for PIK3CA mutation in the tumor were eligible to start MK-2206 (150 mg orally weekly, with prophylactic prednisone) on cycle 1 day 2 (C1D2) and to receive a maximum of four 28-day cycles of combination therapy before surgery. Serial biopsies were collected at preregistration, C1D1 and C1D17. Results: Fifty-one patients preregistered and 16 of 22 with PIK3CA-mutant tumors received study drug. Three patients went off study due to C1D17 Ki67 &gt;10% (n = 2) and toxicity (n = 1). Thirteen patients completed neoadjuvant therapy followed by surgery. No pCRs were observed. Rash was common. MK-2206 did not further suppress cell proliferation and did not induce apoptosis on C1D17 biopsies. Although AKT phosphorylation was reduced, PRAS40 phosphorylation at C1D17 after MK-2206 persisted. One patient acquired an ESR1 mutation at surgery. Conclusions: MK-2206 is unlikely to add to the efficacy of anastrozole alone in PIK3CA-mutant ER+ breast cancer and should not be studied further in the target patient population. Clin Cancer Res; 23(22); 6823–32. ©2017 AACR.
Triheptanoin versus trioctanoin for long‐chain fatty acid oxidation disorders: a double blinded, randomized controlled trial
Gillingham, Melanie B. , Martin, Julie , Rose, Sarah, Goldstein, Amy , El‐Gharbawy, Areeg , DeWard, Stephanie J. , Lasarev, Michael , Pollaro, Jim, DeLany, James P. , Burchill, Luke J. , Shoemaker, James D. , Matern, Dietrich , Heitner, Stephen B. , Goodpaster, Bret H. , Harding, Cary O. , Vockley, Jerry , Burchill, Luke J , Gillingham, Melanie B

Mayo Clinic

Journal of Inherited Metabolic Disease | September 4, 2017 | Volume: 40 | Issue: 6 | Pages: 831-843

10.1007/s10545-017-0085-8 | PMID 28871440 Get It

AbstractBackgroundObservational reports suggest that supplementation that increases citric acid cycle intermediates via anaplerosis may have therapeutic advantages over traditional medium‐chain triglyceride (MCT) treatment of long‐chain fatty acid oxidation disorders (LC‐FAODs) but controlled trials have not been reported. The goal of our study was to compare the effects of triheptanoin (C7), an anaplerotic seven‐carbon fatty acid triglyceride, to trioctanoin (C8), an eight‐carbon fatty acid triglyceride, in patients with LC‐FAODs.MethodsA double blinded, randomized controlled trial of 32 subjects with LC‐FAODs (carnitine palmitoyltransferase‐2, very long‐chain acylCoA dehydrogenase, trifunctional protein or long‐chain 3‐hydroxy acylCoA dehydrogenase deficiencies) who were randomly assigned a diet containing 20% of their total daily energy from either C7 or C8 for 4 months was conducted. Primary outcomes included changes in total energy expenditure (TEE), cardiac function by echocardiogram, exercise tolerance, and phosphocreatine recovery following acute exercise. Secondary outcomes included body composition, blood biomarkers, and adverse events, including incidence of rhabdomyolysis.ResultsPatients in the C7 group increased left ventricular (LV) ejection fraction by 7.4% (p = 0.046) while experiencing a 20% (p = 0.041) decrease in LV wall mass on their resting echocardiogram. They also required a lower heart rate for the same amount of work during a moderate‐intensity exercise stress test when compared to patients taking C8. There was no difference in TEE, phosphocreatine recovery, body composition, incidence of rhabdomyolysis, or any secondary outcome measures between the groups.ConclusionsC7 improved LV ejection fraction and reduced LV mass at rest, as well as lowering heart rate during exercise among patients with LC‐FAODs.Clinical Trial Registration: Clinicaltrials.gov NCT01379625.
Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells
Gil, Małgorzata , Salisbury, Jeffrey L., Goetz, Mathew P., Haddad, Tufia C. , Iankov, Ianko, Kurokawa, Chenye B., Shumacher, Nicole, D’Assoro, Antonino B. , Suman, Vera, Degnim, Amy, Haddad, Tufia, Ingle, James N. , Galanis, Evanthia , D'Assoro, Antonino B, Opyrchal, Mateusz , Goetz, MP, Suman, Vera J. , Degnim, Amy C. , McCubrey, James Andrew

Mayo Clinic

Oncotarget | September 2, 2017 | Volume: 8 | Issue: 53 | Pages: 91803-91816

10.18632/oncotarget.20610 | PMID 29207686 Get It

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Northfelt, Don W., Mahr, Michael A. , Ralya, Andrew T., Kuffel, Mary J., Buhrow, Sarah A. , Safgren, Stephanie L. , McGovern, Renee M., Black, John L. , Dockter, Travis , Haddad, Tufia C. , Erlichman, Charles , Adjei, Alex A. , Visscher, Dan W., Kipp, Benjamin R. , Liu, Minetta C. , Hawse, John R. , Doroshow, James H. , Collins, Jerry M. , Streicher, Howard , Ames, Matthew M. , Élez, Elena , Reid, Joel M. , Kuffel, Mary, Black, John, Haddad, Tufia, Visscher, Dan, Chalmers, Zachary R, Frampton, Garrett, Ingle, James N. , Safgren, Stephanie L , Goetz, Matthew P. , Suman, Vera J. , Chalmers, Zachary Rockow , Frampton, Garrett M. , Elez, Elena

Mayo Clinic

Journal of Clinical Oncology | August 30, 2017 | Volume: 35 | Issue: 30 | Pages: 3391-3400

10.1200/jco.2017.73.3246 | PMID 28854070 Get It

Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estrogen receptor–positive metastatic breast cancer. An accelerated titration schedule was applied until moderate or dose-limiting toxicity occurred, followed by a 3+3 design and expansion at 40, 80, and 100 mg per day. Tumor DNA from serum (circulating cell free [cf); all patients] and biopsies [160 mg/day and expansion]) was sequenced. Results Of 41 enrolled patients, 38 were evaluable for MTD determination. Prior endocrine regimens during which progression occurred included aromatase inhibitor (n = 36), fulvestrant (n = 21), and tamoxifen (n = 15). Patients received endoxifen once daily at seven dose levels (20 to 160 mg). Dose escalation ceased at 160 mg per day given lack of MTD and endoxifen concentrations > 1,900 ng/mL. Endoxifen clearance was unaffected by CYP2D6 genotype. One patient (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus). Overall clinical benefit rate (stable > 6 months [n = 7] or partial response by RECIST criteria [n = 3]) was 26.3% (95% CI, 13.4% to 43.1%) including prior tamoxifen progression (n = 3). cfDNA mutations were observed in 13 patients ( PIK3CA [n = 8], ESR1 [n = 5], TP53 [n = 4], and AKT [n = 1]) with shorter progression-free survival ( v those without cfDNA mutations; median, 61 v 132 days; log-rank P = .046). Clinical benefit was observed in those with ESR1 amplification (tumor; 80 mg/day) and ESR1 mutation (cfDNA; 160 mg/day). Comparing tumor biopsies and cfDNA, some mutations ( PIK3CA, TP53, and AKT) were undetected by cfDNA, whereas cfDNA mutations ( ESR1, TP53, and AKT) were undetected by biopsy. Conclusion In endocrine-refractory metastatic breast cancer, Z-endoxifen provides substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity, and promising antitumor activity.
Mobilization and Transplantation Patterns of Autologous Hematopoietic Stem Cells in Multiple Myeloma and Non-Hodgkin Lymphoma
Costa, Luciano J. , Kumar, Shaji , Stowell, Stephanie A., Dermer, Shari, Costa, Luciano J

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 22 | Issue: 1 | Pages: 87-94

10.1177/107327481502200111 | PMID 25504282 Get It

Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry
Laurino, Mercy , Truitt, Anjali R. , Tenney, Lederle, Fisher, Douglass, Lindor, Noralane M. , Veenstra, David L. , Jarvik, Gail P. , Laurino, Mercy Y , Jarvik, Gail P , Newcomb, Polly A. , Fullerton, Stephanie M.

Mayo Clinic

Molecular Genetics & Genomic Medicine | August 24, 2017 | Volume: 5 | Issue: 6 | Pages: 700-708

10.1002/mgg3.328 | PMID 29178651 Get It

AbstractBackgroundThe extent to which participants act to clinically verify research results is largely unknown. This study examined whether participants who received Lynch syndrome (LS)‐related findings pursued researchers’ recommendation to clinically verify results with testing performed by a CLIA‐certified laboratory.MethodsThe Fred Hutchinson Cancer Research Center site of the multinational Colon Cancer Family Registry offered non‐CLIA individual genetic research results to select registry participants (cases and their enrolled relatives) from 2011 to 2013. Participants who elected to receive results were counseled on the importance of verifying results at a CLIA‐certified laboratory. Twenty‐six (76.5%) of the 34 participants who received genetic results completed 2‐ and 12‐month postdisclosure surveys; 42.3% of these (11/26) participated in a semistructured follow‐up interview.ResultsWithin 12 months of result disclosure, only 4 (15.4%) of 26 participants reported having verified their results in a CLIA‐certified laboratory; of these four cases, all research and clinical results were concordant. Reasons for pursuing clinical verification included acting on the recommendation of the research team and informing future clinical care. Those who did not verify results cited lack of insurance coverage and limited perceived personal benefit of clinical verification as reasons for inaction.ConclusionThese findings suggest researchers will need to address barriers to seeking clinical verification in order to ensure that the intended benefits of returning genetic research results are realized.